Johnson & Johnson announced positive topline results from the Phase 2b JASMINE study of adults living with systemic lupus erythematosus and the initiation of a Phase 3 program. The JASMINE study met ...
(RTTNews) - Jazz Pharmaceuticals plc (JAZZ) announced positive efficacy and safety results from the Phase 3 HERIZON-GEA-01 trial evaluating Ziihera in combination with chemotherapy, with or without ...
The cells in our bodies move in groups during biological processes such as wound healing and tissue development—but because of resistance, or viscosity, those cells can't just neatly glide past each ...
Johnson & Johnson announced positive topline results from its Phase 2 randomized placebo-controlled JASMINE study. The drug therapy, nipocalimab, met its primary endpoint and multiple key secondary ...
Shares of Corvus Pharmaceuticals rose after its investigational drug soquelitinib showed positive results in an early-stage trial in atopic dermatitis patients. The stock surged 50% to $12.10 in ...
WALTHAM, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization ...
Akamai (AKAM) was in focus on Friday as Citi added a Positive Catalyst Watch to the content delivery firm, citing a “potential numbers shift” and a boost from artificial intelligence. “With shares ...
Phase 1b interim results of zumilokibart (APG777) in asthma demonstrated rapid and durable suppression of FeNO (key biomarker of Type 2 inflammation) through 16 weeks for all patients - Suppression of ...
Bristol-Myers Squibb Company (NYSE:BMY) is one of the cheap S&P 500 stocks to invest in now. On January 12, Bristol-Myers Squibb announced positive topline results from its Phase 3 SCOUT-HCM clinical ...
VANCOUVER, BC, Jan. 8, 2026 /PRNewswire/ -- Sustained Therapeutics Inc. ("Sustained Therapeutics" or the "Company"), a clinical-stage therapeutics company developing a non-opioid treatment for pain, ...
BOULDER, Colo., Jan. 8, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results